Vertex Pharmaceuticals (Nasdaq: VRTX) has reported product revenues of $2.3 billion in the third quarter of 2020, an 18% increase on the same period of last year, while upping its revenue guidance for the year to around $8.85 billion.
For the second quarter in a row, the company handily outperformed expectations, with the FT consensus forecast set at $2.23 billion before the announcement.
Net income was $931 million, following Generally Accepted Accounting Principles (GAAP), a 9% jump, giving an earnings per share figure of $3.59.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze